An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.
Approval Alert | Tucatinib Plus Trastuzumab for Advanced HER2+ Metastatic CRC
The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
2
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
3
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
4
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
5
